Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2007 Aug 24;25(44):7674–7686. doi: 10.1016/j.vaccine.2007.08.009

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2007 Elsevier Ltd. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 3 — Cell proliferation response of peripheral blood mononuclear cells after stimulation with vaccine soluble antigen (VSA) (upper left panel) and soluble L. chagasi antigen (SLcA) (upper right panel). The middle and lower panels show the immunophenotypic profile of in vitro peripheral blood mononuclear cells following stimulation with vaccine soluble antigen (VSA) (left panels) and soluble L. chagasi antigen stimulation (right panel) determined at T3 for treatment groups: C (control; □); Sap (saponin; ); LB (killed L. braziliensis vaccine; ); LBSap (killed L. braziliensis vaccine plus saponin; ■). The results are expressed as the mean frequencies of CD5⁺, CD21⁺, CD4⁺ and CD8⁺ cells in the non-stimulated cultures (CC; controls) and in the stimulated cultures (SC). Significant differences (P < 0.05) between values measured at T0 (before the first dose) and T3 (15 days after the third dose) are indicated by connecting lines, and between the LBSap and the control C, Sap, and LB groups at T3 are represented by the letters a, b, and c, respectively.

Inline graphic — Cell proliferation response of peripheral blood mononuclear cells after stimulation with vaccine soluble antigen (VSA) (upper left panel) and soluble L. chagasi antigen (SLcA) (upper right panel). The middle and lower panels show the immunophenotypic profile of in vitro peripheral blood mononuclear cells following stimulation with vaccine soluble antigen (VSA) (left panels) and soluble L. chagasi antigen stimulation (right panel) determined at T3 for treatment groups: C (control; □); Sap (saponin; ); LB (killed L. braziliensis vaccine; ); LBSap (killed L. braziliensis vaccine plus saponin; ■). The results are expressed as the mean frequencies of CD5⁺, CD21⁺, CD4⁺ and CD8⁺ cells in the non-stimulated cultures (CC; controls) and in the stimulated cultures (SC). Significant differences (P < 0.05) between values measured at T0 (before the first dose) and T3 (15 days after the third dose) are indicated by connecting lines, and between the LBSap and the control C, Sap, and LB groups at T3 are represented by the letters a, b, and c, respectively.